References
- ShiboskiCHSchmidtBLJordanRCTongue and tonsil carcinoma: increasing trends in the U.S. population ages 20–44 yearsCancer200510391843184915772957
- ZhangQShiSYenYBrownJTaJQLeADA subpopulation of CD133(+) cancer stem-like cells characterized in human oral squamous cell carcinoma confer resistance to chemotherapyCancer Lett2010289215116019748175
- Perez-SayansMSomoza-MartinJMBarros-AngueiraFDizPGReyJMGarcía-GarcíaAMultidrug resistance in oral squamous cell carcinoma: the role of vacuolar ATPasesCancer Lett2010295213514320418015
- ChongCRJannePAThe quest to overcome resistance to EGFR-targeted therapies in cancerNat Med201319111389140024202392
- RabinowitsGHaddadRIOvercoming resistance to EGFR inhibitor in head and neck cancer: a review of the literatureOral Oncol201248111085108922840785
- FordACGrandisJRTargeting epidermal growth factor receptor in head and neck cancerHead Neck2003251677312478546
- MolinoloAAAmornphimolthamPSquarizeCHCastilhoRMPatelVGutkindJSDysregulated molecular networks in head and neck carcinogenesisOral Oncol2009454–532433418805044
- MuellerKLPowellKMaddenJMEblenSTBoernerJEGFR tyrosine 845 phosphorylation-dependent proliferation and transformation of breast cancer cells require activation of p38 MAPKTransl Oncol20125532733423066441
- LarsenAKOuaretDEl OuadraniKPetitprezATargeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesisPharmacol Ther20111311809021439312
- LindzenMCarvalhoSStarrAA recombinant decoy comprising EGFR and ErbB-4 inhibits tumor growth and metastasisOncogene201231303505351522105361
- DonevISWangWYamadaTTransient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancerClin Cancer Res20111782260226921220474
- SequistLVMartinsRGSpigelDFirst-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutationsJ Clin Oncol200826152442244918458038
- CiardielloFCaputoRBiancoRInhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitorClin Cancer Res2001751459146511350918
- CappuzzoFVarella-GarciaMShigematsuHIncreased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patientsJ Clin Oncol200523225007501816051952
- TanDSWangWLeongHSTongue carcinoma infrequently harbor common actionable genetic alterationsBMC Cancer20141467925234657
- IshiguroYIshiguroHMiyamotoHEpidermal growth factor receptor tyrosine kinase inhibition up-regulates interleukin-6 in cancer cells and induces subsequent development of interstitial pneumoniaOncotarget20134455055923592411
- GusenbauerSVlaicuPUllrichAHGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitorsOncogene201332333846385623045285
- TanakaASueoka-AraganeNNakamuraTCo-existence of positive MET FISH status with EGFR mutations signifies poor prognosis in lung adenocarcinoma patientsLung Cancer2012751899421733594
- FinocchiaroGToschiLGianoncelliLPrognostic and predictive value of MET deregulation in non-small cell lung cancerAnn Transl Med2015368325992382
- SunWSongLAiTPrognostic value of MET, cyclin D1 and MET gene copy number in non-small cell lung cancerJ Biomed Res201327322023023720678
- NoroRSeikeMZouFMET FISH-positive status predicts short progression-free survival and overall survival after gefitinib treatment in lung adenocarcinoma with EGFR mutationBMC Cancer2015153125886066
- EngelmanJAZejnullahuKMitsudomiTMET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signalingScience200731658271039104317463250
- HuangKLiuDTargeting non-canonical autophagy overcomes erlotinib resistance in tongue cancerTumour Biol20163779625963326797786